Primary Signet Ring Cell Carcinoma of the Prostate

Abstract

Nine patients treated with primary signet ring cell carcinoma of the prostate were identified among 29,783 cases of prostate cancer evaluated at Mayo Clinic from January 15, 1970, until January 2, 2009. A PubMed search of the English-language literature published from January 1, 1980, to January 1, 2010, was then performed using the key words signet ring cell and prostate, identifying 42 cases. This study reviews those cases, along with the additional 9 reported herein, and evaluates clinical characteristics, histologic diagnoses, treatment modalities, and outcomes. Mean age at diagnosis was 68 years (range, 50-85 years), and mean prostate-specific antigen level was 95.3 ng/mL (range, 1.9-536.0 ng/mL; to convert to μg/L, multiply by 1). Most patients (66%) had non-stage IV carcinoma, the most common Gleason sum was 8 (33%), and mean survival was 29 months. The presence of a primary signet ring cell carcinoma of the prostate was best confirmed by negative findings on gastrointestinal work-up, a positive stain for prostate-specific acid phosphatase, and negative carcinoembryonic antigen test results.

Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy

“…One such case was reported by Akagashi et al where hormonal therapy alone was used and the follow-up was 20 months and another was reported by Lilleby et al 5 where neoadjuvant hormone with radiation was employed and the patient was followed for 12 months. Another recently published series of nine patients by Warner et al 6 have shown varying survival rates ranging from 5 months to 9 years depending on the stage and treatment received. Our patient is doing well and has no evidence of disease progression or metastasis at 24-month follow-up.…”

A Primary Signet Ring Cell Carcinoma of the Prostate With Bone Metastasis With Impressive Response to FOLFOX and Cetuximab

“…SRCC of the prostate rarely responds to hormonal manipulation. 5 Elevation of PSA levels as a tumor marker for SRCC of the prostate has not been consistently observed in the literature. To the best of our knowledge, the present case is the first SRCC of the prostate to be treated with colorectal chemotherapy.…”

“…5 The diagnosis of primary prostatic SRCC requires that 25% or more of the tumor be composed of signet ring cells. 6 There is a lack of data regarding the molecular etiology of signet ring cells.…”

Expression of CD7, CD20 and CDX-2 in a Secondary Signet-Ring Cell Tumor of the Prostate: A Case Report

“…Although SRCC (signet-ring cell carcinoma) is primarily found in the stomach and colon, it can also be found in the pancreas, breast, thyroid, bladder and prostate (1).…”